SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors grapple with the implications of increased AI spending and a one-time tax charge impacting earnings, leading to community debates on whether the dip is a buying opportunity or a sign of deeper concerns. Community members are actively discussing potential support levels, options activity, and whether the stock is oversold, while others express frustration with the stock's recent performance. Despite the concerns, some bulls remain confident in META's long-term potential and ability to monetize its massive user base.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors discuss its potential trigger points and market control, with some expressing excitement about options and long-term prospects. The community is highlighting QNX integration with NVIDIA chips and government support for Canadian businesses, while also pondering potential drivers for recent market activity and keeping an eye on upcoming announcements.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending as the community discusses a recent event involving an FDA official's social media post and its impact on the stock. Traders are evaluating the situation, with some speculating about a potential buying opportunity, while others express concerns about the company's response and the need for accountability. Investors are closely watching for further developments and any potential impact on the company's prospects, particularly regarding upcoming earnings and AUR200.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as investors discuss its potential role in powering AI data centers with its natural gas fuel cell technology, drawing comparisons to Bloom Energy's success in the sector. Community members are closely watching for news of new contracts and partnerships, anticipating a significant impact on the stock's valuation given its smaller market cap compared to its peers. Some believe that the company is undervalued and that a squeeze is coming.

Ucore Rare Metals, Inc. Is a technology company, which engages in the business of metal separation products, and services to the mining and mineral extraction industry. Its projects include Bokan-Dotson Ridge Rare Earth Element. The company was founded on October 5, 2006 and is headquartered in Halifax, Canada.

Ucore Rare Metals Inc

Ucore Rare Metals Inc.

Ucore Rare Metals is trending amid speculation of upcoming deals with the Canadian government, potentially mirroring recent offtake agreements in the critical minerals sector. Community members are excited about Ucore's refining capabilities and its role in establishing North American supply chain independence, especially with the G7 summit underway. Trading halts and price volatility reflect both anticipation and nervousness as investors await news.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

LUMN is trending as investors rally behind the company's AI-driven turnaround story following a narrowed Q3 loss and new AI-driven connectivity deals. The community is actively discussing the potential for a significant bounce, with some anticipating a short squeeze and a run to higher price levels. Bullish sentiment is fueled by the improving outlook and strategic partnerships, positioning LUMN as a key player in the AI infrastructure space.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

GALT is trending as investors anticipate upcoming presentations at the AASLD Liver Meeting in November, with the community closely watching for potential partnership or buyout news before year-end. Discussions center on the value of Belapectin, especially in combination with GLP-1 drugs, and the possibility of a short squeeze given the high short interest. Community members are actively debating potential buyout prices and the impact of upcoming presentations on the stock's valuation.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu is gaining attention as community members point to strong accumulation patterns and increasing bullish sentiment. Discussions highlight the potential for a significant move as market participants quietly position themselves. The focus remains on the underlying strength and the anticipation of a coming breakout.

NewcelX Ltd.

NCEL is trending due to the completion of its merger with Kadimastem, alongside a planned reverse split and ticker change, generating both excitement and confusion. Community members are actively discussing the mechanics of the merger, reverse split, and potential short squeeze scenarios. Traders are also debating appropriate valuations and entry/exit points amidst the volatility.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to its low float, leading to discussions of potential squeezes and comparisons to other high-momentum stocks like HKD and CURR. The community is actively watching for breakouts, particularly above the $15 mark, with some anticipating a run towards $20. Recent trading patterns and potential for high percentage gains are also fueling the interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sinovac Biotech saw a sharp uptick in retail investor interest late Sunday after the company disclosed a legal win that paves the way for a $55 per share special cash dividend, payable on July 7.The U.S. District Court for the Southern District of New York denied a petition for emergency injunctive relief filed by Advantech/Prime Success, a member of the so-called “Dissenting Investor Group” that includes Vivo Capital.&nbsp;The group had sought to block the current board from executing the dividend payout, which follows a broader dispute over corporate control and the legitimacy of prior board actions.The court ruling clears a major legal obstacle for the current Sinovac Board, which was installed following a Privy Council order and proceedings under Antiguan law.&nbsp;The board now has a clear path to disburse the $55 dividend through its designated paying agent.In a statement, Sinovac said that if it succeeds in separate legal proceedings in Antigua to cancel disputed Private Investment in Public Equity (PIPE) shares issued by the previous board, it intends to distribute an additional $11 per share to valid shareholders.Sinovac accused the dissenting group of deploying “multi-pronged lawfare” to prevent valid shareholders from receiving dividends unless PIPE shares, which the current board deems invalid, were included.&nbsp;According to Sinovac, over $1 billion has already been paid to the dissenting group via a Sinovac operating unit.The board has placed the pro rata portion of dividend funds for disputed PIPE shares in escrow, pending the outcome of the ongoing litigation.In parallel, Sinovac is preparing for a special shareholder meeting on July 8, at which investors will vote on two proposals to replace the current board.&nbsp;The company urged shareholders to vote “against” both proposals and to support the existing leadership.On Stocktwits, retail sentiment was ‘neutral’ amid ‘high’ message volume.Sinovac’s shares remain halted from trading on Nasdaq and have not changed hands since February 2019.&nbsp;The trading suspension followed prolonged governance disputes, including contested PIPE share issuances and competing board claims.&nbsp;Although recent court rulings have favored the current board and cleared the way for a planned dividend payout, the company has not announced a timeline for resuming trading or disclosed whether it has met Nasdaq’s requirements for relisting.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Chinese Sinovac vaccine for Covid-19 logo seen displayed on a smartphone. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Sinovac Clears Legal Hurdle In Control Battle, Moves Forward With $55 Dividend 

A U.S. court denied an emergency injunction sought by dissenting investors, while a separate case in Antigua could unlock an additional $11 per share if disputed PIPE shares are invalidated.

Equity

SINOVAC Issues Statement Regarding Privy Council Judgment

Sinovac Biotech Ltd. (NASDAQ:SVA) ('SINOVAC' or the 'Company'), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London...

SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)

Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III clinical trial on a vaccine...

SINOVAC Reports Unaudited First Half of 2024 Financial Results

Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June...

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and...

Sinovac Amends Shareholder Rights Plan

Sinovac Biotech Ltd. (Sinovac or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights...

Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the Board of Directors...

Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps. The company was founded in 1993 and is headquartered in Beijing, China.

Sinovac Biotech, Ltd.

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

SVA
Sinovac Biotech, Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SVA News

SVASinovac Biotech, Ltd.